R1 RCM Inc. (NASDAQ:RCM) Shares Bought by Marshall Wace LLP

Marshall Wace LLP grew its holdings in R1 RCM Inc. (NASDAQ:RCM) by 762.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 627,387 shares of the healthcare provider’s stock after acquiring an additional 554,671 shares during the quarter. Marshall Wace LLP owned 0.15% of R1 RCM worth $7,880,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Advisors Asset Management Inc. purchased a new stake in R1 RCM during the 1st quarter valued at about $27,000. ANTIPODES PARTNERS Ltd purchased a new position in R1 RCM during the 2nd quarter worth approximately $86,000. QRG Capital Management Inc. purchased a new position in R1 RCM during the 1st quarter worth approximately $132,000. Caas Capital Management LP acquired a new stake in R1 RCM during the 4th quarter valued at approximately $148,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of R1 RCM in the 2nd quarter valued at $149,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

Analyst Ratings Changes

RCM has been the subject of several analyst reports. Jefferies Financial Group cut R1 RCM from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $14.30 price objective on shares of R1 RCM in a research note on Tuesday, August 20th. TD Cowen reiterated a “hold” rating and issued a $14.30 target price (down from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Leerink Partners lowered shares of R1 RCM from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $17.00 to $14.30 in a research report on Thursday, August 1st. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $18.00 price objective on shares of R1 RCM in a research report on Tuesday, July 2nd. Thirteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $15.41.

R1 RCM Price Performance

Shares of NASDAQ RCM opened at $14.17 on Monday. The stock has a market cap of $5.97 billion, a PE ratio of -177.13 and a beta of 0.84. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.77. R1 RCM Inc. has a 12-month low of $8.87 and a 12-month high of $15.43. The company has a 50-day moving average of $13.91 and a 200 day moving average of $13.00.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. R1 RCM had a negative return on equity of 1.44% and a negative net margin of 1.68%. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $633.10 million. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, sell-side analysts predict that R1 RCM Inc. will post -0.24 EPS for the current fiscal year.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.